Plx pharma inc. (PLXP)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)

-20,502

896

-15,346

-4,905

-18,742

-13,580

-4,013

Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization

158

200

29

3

-

-

-

Stock-based compensation

875

841

1,624

2,471

3,275

1,418

1,077

Amortization of debt discounts and issuance costs

215

247

-

-

-

-

-

Impairment of intangible assets

-

-

2,294

0

-

-

-

Non-cash interest expense

-

-

724

-

-

-

-

Non-cash interest expense

-

-

-

0

-

-

-

Change in fair value of warrant liability

5,710

-12,705

-633

0

-

-

-

Provision for obsolete inventory

-

770

319

0

-

-

-

Loss on sale of property and equipment

-12

-

-

-

-

-

-

Expenses allocated to warrant liability

-

-

1,302

0

-

-

-

Deferred tax benefit

-

-

-920

0

-

-

-

Share-Based Payments to Vendors

-

-

-

-

575

-

-

Share-Based Payments to Vendors

-

-

-

-

-

450

123

Amortization of short-term investment interest income

-

-

-

-

20

-

-

Executive Compensation Settled with Membership Interests

-

-

-

-

-

-

115

Changes in operating assets and liabilities:
Accounts receivable

0

-1

14

5

-

-

-

Inventory

-

524

449

116

-

-

-

Prepaid expenses and other assets

-152

109

223

-13

-

-

-

Vendor deposit

-

-707

715

0

-

-

-

Right of use assets

-94

-

-

-

-

-

-

Prepaid expenses

-

-

-

-

26

74

39

Security Deposit

-

-

-

-

0

-49

3

Accounts payable and accrued liabilities

448

-194

-109

633

345

559

538

Accrued bonuses

118

198

-1,434

0

-

-

-

Accrued interest

166

225

229

64

-

-

-

Other current and long-term liabilities

-109

-55

-

-

-

-

-

Accrued interest - related parties

-

-

13

30

-

-

-

Deferred revenue

-

-

-200

0

-

-

-

Other current and long-term liabilities

-

-

201

0

-

-

-

Net cash used in operating activities

-12,659

-9,499

-13,306

-1,810

-

-

-

CASH FLOWS FROM INVESTING ACTIVITIES
Net cash used in operating activities

-

-

-

-

-14,592

-11,276

-2,194

Purchases of property and equipment

241

654

537

0

-

-

-

Proceeds from sale of property and equipment

11

-

-

-

-

-

-

Proceeds from issuance of Common Stock, net of issuance costs

-

-

-

-

19,743

-

-

Net cash used in investing activities

-230

-654

11,238

0

-

-

-

CASH FLOWS FROM FINANCING ACTIVITIES
Cash received in business combination

-

-

11,776

0

-

-

-

Net proceeds from issuance of convertible Series A preferred stock

13,661

-

-

-

-

-

-

Net proceeds from issuance of common stock

2,103

-

-

-

-

-

-

Repayments of term loan

3,125

-

-

-

-

-

-

Proceeds from Short-term Investments

-

-

-

-

4,000

-

-

Purchase of Short-term Investments

-

-

-

-

30,956

-

-

Net cash provided by investing activities

-

-

-

-

-26,956

-

-

Proceeds from issuance of convertible notes payable

-

-

460

1,297

-

-

-

Proceeds from issuance of convertible notes payable - related parties

-

-

108

480

-

-

-

Proceeds from Dipexium note

-

-

2,000

0

-

-

-

Proceeds from equity offering, net of allocated issuance costs

-

-

16,698

0

-

-

-

Proceeds from issuance of term loan, net of fees

-

-

7,145

0

-

-

-

Net cash (used in) provided by financing activities

12,640

-

26,412

1,777

-

-

-

Proceeds from issuance of Common Stock, net of issuance costs

-

-

-

-

-

34,455

-

Proceeds from Private Placement Offerings, net of issuance costs

-

-

-

-

-

-

4,598

Net cash provided by financing activities

-

-

-

-

19,743

34,455

4,598

Net Decrease In Cash and Cash Equivalents

-

-

-

-

-21,805

-

-

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS

-248

-10,154

24,345

-32

-

23,179

2,404

SUPPLEMENTAL INFORMATION
Income taxes

-

-

-

0

-

-

-

Interest

600

671

195

0

-

-

-

NON-CASH INVESTING AND FINANCING TRANSACTIONS
Property and equipment included in accounts payable

12

-

89

0

-

-

-

Deferred financing costs included in accounts payable and accrued liabilities

-

174

-

-

-

-

-

Preferred stock beneficial conversion feature and dividends

13,750

-

-

-

-

-

-

Value of common shares issued to vendor for services

45

90

60

0

0

-

-

Value of common shares issued in business combination

-

-

15,048

0

-

-

-

Value of common shares issued upon conversion of debt and accrued interest

-

-

2,495

0

-

-

-

Equity offering proceeds allocated to warrant liability

-

-

15,876

0

-

-

-

Term loan proceeds allocated to warrant

-

-

304

0

-

-

-